Treatment interruption in a primary care antiretroviral therapy program in South Africa: Cohort analysis of trends and risk factors

Journal of Acquired Immune Deficiency Syndromes

Volumn 55, Issue 3, 2010, Pages

  Kranzer, Katharina ^a,b   Lewis, James J ^b,c   Ford, Nathan ^a   Zeinecker, Jennifer ^a   Orrell, Catherine ^a   Lawn, Stephen D ^a,b   Bekker, Linda Gail ^a   Wood, Robin ^a  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

^b LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^c AURUM INSTITUTE   (South Africa)

Author keywords

Africa; antiretroviral; HIV; loss to follow up; unstructured treatment interruption

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; FEMALE; FOLLOW UP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; SOUTH AFRICA; COHORT ANALYSIS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV INFECTIONS; PRIMARY HEALTH CARE; RISK FACTOR; STATISTICS AND NUMERICAL DATA; TREATMENT WITHDRAWAL; TRENDS;

ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; COHORT STUDIES; FEMALE; HIV INFECTIONS; HUMANS; MALE; PRIMARY HEALTH CARE; RISK FACTORS; SOUTH AFRICA; WITHHOLDING TREATMENT;

EID: 78049281900     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAI.0b013e3181f275fd     Document Type: Article

References (37)

1. World Health Organization. Towards Universal Access: Scaling Up Priority HIV/AIDS Interventions in the Health Sector: Progress Report 2009. Geneva, Switzerland: World Health Organization; 2009. Available at: http://www.who.int/ hiv/pub/tuapr-2009-en.pdf last. Accessed April 16, 2010.
2. Mills EJ, Nachega JB, Bangsberg DR, et al. Adherence to HAART: a systematic review of developed and developing nation patient-reported barriers and facilitators. PLoS Med. 2006;3:e438.
3. Nachega JB, Mills EJ, Schechter M. Antiretroviral therapy adherence and retention in care in middle-income and low-income countries: current status of knowledge and research priorities. Curr Opin HIV AIDS. 2010; 5(1):70-77.
4. Karcher H, Omondi A, Odera J, et al. Risk factors for treatment denial and loss to follow-up in an antiretroviral treatment cohort in Kenya. Trop Med Int Health. 2007;12:687-694.
5. Orrell C, Bangsberg DR, Badri M, et al. Adherence is not a barrier to successful antiretroviral therapy in South Africa. AIDS. 2003;17: 1369-1375.
6. Brinkhof MW, Dabis F, Myer L, et al. Early loss of HIV-infected patients on potent antiretroviral therapy programmes in lower-income countries. Bull World Health Organ. 2008;86:559-567.
7. Brinkhof MW, Pujades-Rodriguez M, Egger M. Mortality of patients lost to follow-up in antiretroviral treatment programmes in resource-limited settings: systematic review and meta-analysis. PLoS One. 2009;4:e5790.
8. Rosen S, Fox MP, Gill CJ. Patient retention in antiretroviral therapy programs in sub-Saharan Africa: a systematic review. PLoS Med. 2007;4: e298.
9. Lawn SD, Harries AD, Anglaret X, et al. Early mortality among adults accessing antiretroviral treatment programmes in sub-Saharan Africa. AIDS. 2008;22:1897-1908.
10. Bisson GP, Gaolathe T, Gross R, et al. Overestimates of survival after HAART: implications for global scale-up efforts. PLoS One. 2008;3:e1725.
11. Holkmann Olsen C, Mocroft A, Kirk O, et al. Interruption of combination antiretroviral therapy and risk of clinical disease progression to AIDS or death. HIV Med. 2007;8:96-104.
12. Touloumi G, Pantazis N, Antoniou A, et al. Highly active antiretroviral therapy interruption: predictors and virological and immunologic consequences. J Acquir Immune Defic Syndr. 2006;42:554-561.
13. Taffe P, Rickenbach M, Hirschel B, et al. Impact of occasional short interruptions of HAARTon the progression of HIV infection: results from a cohort study. AIDS. 2002;16:747-755.
14. d'arminio Monforte A, Cozzi-Lepri A, Phillips A, et al. Interruption of highly active antiretroviral therapy in HIV clinical practice: results from the Italian Cohort of antiretroviral-naive patients. J Acquir Immune Defic Syndr. 2005;38:407-416.
15. + guided antiretroviral treatment interruption in HIV infection: a meta-analysis. AIDS Rev. 2008; 10:236-244.
16. + count-guided interruption of antiretroviral treatment. N Engl J Med. 2006;355: 2283-2296.
17. Mugyenyi P, Walker A, Hakim J, et al. Fixed duration interruptions are inferior to continuous treatment in African adults starting therapy with CD4 cell counts ,200 cells/microl. AIDS. 2008;22:237-247.
18. Skiest DJ, Morrow P, Allen B, et al. It is safe to stop antiretroviral therapy in patients with preantiretroviral CD4 cell counts.250 cells/microL. J Acquir Immune Defic Syndr. 2004;37:1351-1357.
19. Poulton MB, Sabin CA, Fisher M. Immunological changes during treatment interruptions: risk factors and clinical sequelae. AIDS. 2003;17: 126-128.
20. Sungkanuparph S, Kiertiburanakul S, Apisarnthanarak A, et al. Rapid CD4 decline after interruption of non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy in a resource-limited setting. AIDS Res Ther. 2007;4:26.
21. Oyugi JH, Byakika-Tusiime J, Ragland K, et al. Treatment interruptions predict resistance in HIV-positive individuals purchasing fixed-dose combination antiretroviral therapy in Kampala, Uganda. AIDS. 2007;21: 965-971.
22. Bansi LK, Benzie AA, Phillips AN, et al. Are previous treatment interruptions associated with higher viral rebound rates in patients with viral suppression? AIDS. 2008;22:349-356.
23. Parienti JJ, Das-Douglas M, Massari V, et al. Not all missed doses are the same: sustained NNRTI treatment interruptions predict HIV rebound at low-to-moderate adherence levels. PLoS ONE. 2008;3:e2783.
24. Wood R, Middelkoop K, Myer L, et al. Undiagnosed tuberculosis in a community with high HIV prevalence: implications for tuberculosis control. Am J Respir Crit Care Med. 2007;175:87-93.
25. Remien RH, Chowdhury J, Mokhbat JE, et al. Gender and care: access to HIV testing, care, and treatment. J Acquir Immune Defic Syndr. 2009; 51(Suppl 3):S106-S110.
26. Muula AS, Ngulube TJ, Siziya S, et al. Gender distribution of adult patients on highly active antiretroviral therapy (HAART) in Southern Africa: a systematic review. BMC Public Health. 2007;7:63.
27. Amuron B, Namara G, Birungi J, et al. Mortality and loss-to-follow-up during the pre-treatment period in an antiretroviral therapy programme under normal health service conditions in Uganda. BMC Public Health. 2009;9:290.
28. Cornell M, Myer L, Kaplan R, et al. The impact of gender and income on survival and retention in a South African antiretroviral therapy programme. Trop Med Int Health. 2009;14:722-731.
29. MacPherson P, Moshabela M, Martinson N, et al. Mortality and loss to follow-up among HAART initiators in rural South Africa. Trans R Soc Trop Med Hyg. 2009;103:588-593.
30. Zachariah R, Harries K, Moses M, et al. Very early mortality in patients starting antiretroviral treatment at primary health centres in rural Malawi. Trop Med Int Health. 2009;14:713-721.
31. Sieleunou I, Souleymanou M, Schonenberger AM, et al. Determinants of survival in AIDS patients on antiretroviral therapy in a rural centre in the Far-North Province, Cameroon. Trop Med Int Health. 2009;14:36-43.
32. Manosuthi W, Chaovavanich A, Tansuphaswadikul S, et al. Incidence and risk factors of major opportunistic infections after initiation of antiretroviral therapy among advanced HIV-infected patients in a resource-limited setting. J Infect. 2007;55:464-469.
33. Nachega JB, Hislop M, Dowdy DW, et al. Adherence to highly active antiretroviral therapy assessed by pharmacy claims predicts survival in HIV-infected South African adults. J Acquir Immune Defic Syndr. 2006; 43:78-84.
34. Assefa Y, Van Damme W, Hermann K. Human resource aspects of antiretroviral treatment delivery models: current practices and recommendations. Curr Opin HIV AIDS. 2010;5(1):78-82.
35. Dahab M, Charalambous S, Hamilton R, et al. "That is why I stopped the ART": patients' & providers' perspectives on barriers to and enablers of HIV treatment adherence in a South African workplace programme. BMC Public Health. 2008;8:63.
36. World Health Organization.Rapid Advice: Antiretroviral Therapy for HIV Infection in Adults and Adolescents. Geneva, Switzerland: World Health Organization 2009. Available at: http://www.who.int/hiv/pub/arv/rapid- advice-art.pdf. Accessed March 2010.
37. Granich RM, Gilks CF, Dye C, et al. Universal voluntary HIV testing with immediate antiretroviral therapy as a strategy for elimination of HIV transmission: a mathematical model. Lancet. 2009;373:48-57.